Evidence map›Paper›PMID 29855975›Full record

ArticleAIDS and behavior2018

Contraceptive Preference Among Women at Risk of HIV Acquisition in a Preparatory Screening Study for a Phase III Microbicide Trial in South Western Uganda.

Sylvia Kusemererwa, Andrew Abaasa, Martin Onyango, Annalene M Nel, Michelle Isaacs, Gershim Asiki

Registry-linked trialAbstract read
In one paragraph

Article in AIDS and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01539226 (A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01539226 nacompletednot on this map

A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women

TypeinterventionalSponsorInternational Partnership for Microbicides, Inc.Ran2012 to 2016Enrolled1,959ConditionsHIV InfectionsArmsPlacebo Vaginal Ring, Dapivirine Vaginal Ring, 25 mg
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sylvia KusemererwaMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda. Sylvia.Kusemererwa@mrcuganda.org.ORCID http://orcid.org/0000-0002-1390-109X
Andrew AbaasaMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Martin OnyangoMRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.
Annalene M NelInternational Partnership for Microbicides (IPM), Silver Spring, MA, USA.
Michelle IsaacsInternational Partnership for Microbicides (IPM), Silver Spring, MA, USA.
Gershim AsikiAfrican Population and Health Research Centre (APHRC), Health and Systems for Health Unit Department, Nairobi, Kenya.

Funding

Int'l Traineeships in AIDS Prevention Studies (ITAPS)R25MH064712 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LINDAN, CHRISTINA P · 2002 to 2018
$3.4M
International Partnership for Microbicides 659International Partnership for Microbicides IND # 110International Partnership for Microbicides IPMNIMH NIH HHS R25 MH064712
6 · The paper itself

Abstract

Contraceptive preferences of women at risk for HIV acquisition are not well documented. We report on contraceptive choices among women residing in small townships in southwestern Uganda. This was part of preparatory efforts for recruitment into the Ring Study, a phase 3 microbicide trial, between July 2013 and October 2014. Clinicians provided contraceptives per a woman's choice. HIV testing and screening for other sexually transmitted infections were done at first contact and at screening for the trial. Contraceptive choice was summarized by demographics and regression analysis to show factors associated with use of the injectable method. Of 6725 women contacted, 489 were prescreened. Of these 489 women, most (306, 63%) were already using contraception. Injectables were most preferred (58.7%), followed by implants (23.9%). Women living with a regular sexual partner preferred the injectable method (61.0%, P = 0.06), compared with other methods. Women at risk for HIV infection are willing to initiate use of modern contraceptives, which may reduce study dropout during intervention trials due to unintended pregnancy. Registration no: NCT01539226.

Indexed as

Clinical Trials, Phase III as TopicAdultAnti-Infective AgentsContraceptionContraceptive Agents, FemaleDrug ImplantsFemaleHIV InfectionsHumansInjectionsPatient PreferencePregnancyUgandaYoung AdultAnti-Infective AgentsContraceptive Agents, FemaleDrug ImplantsContraceptive preferenceContraceptivesUgandaWomen at high-risk

Identifiers

PMID29855975
PMCPMC6128163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.